Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome

Giovanni Targher; Giacomo Zoppini; Enzo Bonora; Paolo Moghetti

doi:10.1055/s-0034-1384512

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2014; 40(05): 600-618
DOI: 10.1055/s-0034-1384512

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome^[*]

Authors

Giovanni Targher

¹Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Giacomo Zoppini

¹Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Enzo Bonora

¹Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Paolo Moghetti

¹Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

Abstract

Polycystic ovary syndrome (PCOS) is the most common form of anovulatory infertility, affecting up to 10% of women of reproductive age. This syndrome was first described in 1935 when American gynecologists Stein and Leventhal associated the presence of ovarian cysts with anovulation, obesity, and hirsutism. For many years, the effects of PCOS on coagulation and fibrinolysis have remained largely unexplored. This review summarizes current knowledge of the effects of PCOS on coagulation and fibrinolysis, and the putative mechanisms by which PCOS may contribute to the development of coagulation and fibrinolytic disorders. To date, there is relatively strong evidence suggesting that PCOS is associated with increased platelet aggregation and decreased plasma fibrinolytic activity. However, whether these hemostatic disorders are linked to the abnormal hormonal system in PCOS remains to be elucidated. Moreover, it should be emphasized that PCOS is a heterogeneous endocrine condition, and that the number of published studies is limited, the sample size of most of these studies is relatively small, and the selection of control subjects has not been always appropriate. Furthermore, well-designed studies on larger cohorts of carefully characterized PCOS patients are needed to provide more comprehensive information on this issue.

Keywords

hemostasis - polycystic ovary syndrome - thrombosis

Full Text

References

References
1 Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13
2 Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 2009; 35 (7) 613-620
3 Targher G, Pichiri I, Zoppini G, Bonora E, Chonchol M. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. Semin Thromb Hemost 2009; 35 (7) 605-612
4 Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29: 181-191
5 Hanson AE. Hippocrates: Diseases of Women 1. Signs (Chic) 1975; 1: 567-584
6 Temkin O. Soranus' Gynecology. Book I. Baltimore, MA: The Johns Hopkins University Press; 1991
7 Vallisneri A. Istoria della generazione dell'uomo, e degli animali, se sia da' vermicelli spermatici, o dalle uova: con un trattato nel fine della sterilità, e de' suoi rimedj; con la critica de' superflui, e de' nocivi; con un discorso accademico intorno la connessione di tutte le cose create; e con alcune lettere, istorie rare, osservazioni d'uomini illustri. Gio. Gabbriel Hertz ed., Venice 1721: 146
8 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19 (1) 41-47
9 Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, , eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific Publications; 1992: 377-384
10 March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25 (2) 544-551
11 Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012; 27 (10) 3067-3073
12 Azziz R, Carmina E, Dewailly D , et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11) 4237-4245
13 Moghetti P, Tosi F, Bonin C , et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98 (4) E628-E637
14 Legro RS, Arslanian SA, Ehrmann DA , et al; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98 (12) 4565-4592
15 Kelly CJG, Lyall H, Petrie JR , et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002; 87 (7) 3287-3290
16 Dereli D, Ozgen G, Buyukkececi F, Guney E, Yilmaz C. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003; 88 (5) 2263-2268
17 Gursoy A, Ertugrul DT, Pamuk B , et al. Mean platelet volume in patients with polycystic ovary disease. Platelets 2006; 17 (7) 505-506
18 Oktem M, Ozcimen EE, Uckuyu A , et al. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 2009; 91 (6) 2545-2550
19 Rajendran S, Willoughby SR, Chan WPA , et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009; 204 (2) 509-514
20 Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond) 2009; 116 (10) 761-770
21 Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280 (2) 187-193
22 Luque-Ramírez M, Mendieta-Azcona C, del Rey Sánchez JM, Matíes M, Escobar-Morreale HF. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. Eur J Endocrinol 2009; 160 (3) 469-480
23 Yildiz BO, Bozdag G, Harmanci A , et al. Increased circulating soluble P-selectin in polycystic ovary syndrome. Fertil Steril 2010; 93 (7) 2311-2315
24 Mannerås-Holm L, Baghaei F, Holm G , et al. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011; 96 (4) 1068-1076
25 Koiou E, Tziomalos K, Katsikis I , et al. Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones (Athens) 2012; 11 (1) 77-85
26 Koiou E, Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Panidis D. Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome. Gynecol Endocrinol 2013; 29 (3) 250-253
27 Kahal H, Aburima A, Ungvari T , et al. Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. Clin Endocrinol (Oxf) 2013; 79 (2) 252-258
28 Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69 (2) 236-241
29 Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87 (8) 3871-3875
30 Słopień R, Lewandowski K, Kolacz E, Zawilska K, Warenik-Szymankiewicz A. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. Gynecol Endocrinol 2006; 22 (11) 651-654
31 Erdoğan M, Karadeniz M, Alper GE , et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2008; 116 (3) 143-147
32 Karakurt F, Gumus II, Bavbek N , et al. Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 2008; 24 (9) 491-497
33 Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25 (2) 110-116
34 González F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost 2013; 19 (1) 66-72
35 de Mendonça-Louzeiro MRMF, Annichino-Bizzacchi JM, Magna LA, Quaino SK, Benetti-Pinto CL. Faster thrombin generation in women with polycystic ovary syndrome compared with healthy controls matched for age and body mass index. Fertil Steril 2013; 99 (6) 1786-1790
36 Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45 (5) 623-629
37 Atiomo WU, Fox R, Condon JE , et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000; 52 (4) 487-492
38 Tarkun I, Cantürk Z, Arslan BC, Türemen E, Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004; 51 (5) 467-472
39 Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004; 150 (6) 793-798
40 Orio Jr F, Palomba S, Cascella T , et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reprod Biomed Online 2004; 9 (5) 505-510
41 Carmassi F, De Negri F, Fioriti R , et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005; 116 (3) 207-214
42 Lin S, Yongmei G. Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome. Int J Gynaecol Obstet 2008; 100 (3) 285-286
43 Lin S, Huiya Z, Bo L, Wei W, Yongmei G. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome. Endocrine 2009; 36 (3) 503-509
44 González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009; 58 (7) 954-962
45 Lindholm A, Bixo M, Eliasson M , et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2010; 26 (10) 743-748
46 Koiou E, Tziomalos K, Dinas K , et al. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocr J 2012; 59 (1) 21-29
47 Atiomo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Prentice AG. Are women with polycystic ovary syndrome resistant to activated protein C?. Fertil Steril 2000; 74 (6) 1229-1232
48 Tsanadis G, Vartholomatos G, Korkontzelos I , et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 2002; 17 (2) 314-319
49 Adali E, Yildizhan R, Kurdoglu M, Bugdayci G, Kolusari A, Sahin HG. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in young obese women with polycystic ovary syndrome. Fertil Steril 2010; 94 (2) 666-672
50 Moini A, Tadayon S, Tehranian A, Yeganeh LM, Akhoond MR, Yazdi RS. Association of thrombophilia and polycystic ovarian syndrome in women with history of recurrent pregnancy loss. Gynecol Endocrinol 2012; 28 (8) 590-593
51 Heutling D, Schulz H, Nickel I , et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93 (1) 82-90
52 Charitidou C, Farmakiotis D, Zournatzi V , et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008; 196 (2) 958-965
53 Pamuk BO, Torun AN, Kulaksizoglu M , et al. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril 2010; 93 (4) 1227-1233
54 Burchall G, Linden MD, Teede H, Piva TJ. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome. Trends Cardiovasc Med 2011; 21 (1) 6-14
55 Diamanti-Kandarakis E, Paterakis T, Kandarakis HA. Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci 2006; 1092: 175-186
56 Pai JK, Pischon T, Ma J , et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351 (25) 2599-2610
57 Haverkate F. Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 2002; 39 (3) 109-112
58 Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011; 95 (3) 1048-1058 , e1–e2
59 Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. Metabolism 2013; 62 (11) 1587-1596
60 Olufadi R, Byrne CD. Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 2006; 35 (3-4) 281-291
61 Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006; 98 (11) 1352-1364
62 Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18 (7) 280-285
63 Roe A, Hillman J, Butts S , et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab 2014; 99 (5) E841-E847
64 Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci 2013; 56 (3) 137-142
65 Chen Y, Billadello JJ, Schneider DJ. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol 2000; 20 (12) 2696-2701
66 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10 (6) 330-344
67 Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363 (14) 1341-1350
68 Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost 2013; 39 (2) 214-228
69 Targher G, Zoppini G, Moghetti P, Day CP. Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 2010; 36 (1) 41-48
70 Karoli R, Fatima J, Chandra A, Gupta U, Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci 2013; 6 (1) 9-14
71 Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33 (7) 801-814
72 Jones H, Sprung VS, Pugh CJ , et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab 2012; 97 (10) 3709-3716
73 Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 2013; 40: 40-50
74 Gupta V, Bhasin S, Guo W , et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008; 296 (1-2) 32-40
75 Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132 (6) 2169-2180
76 Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost 2013; 110 (4) 669-680
77 Stegenga ME, van der Crabben SN, Levi M , et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55 (6) 1807-1812
78 Allan CA. Sex steroids and glucose metabolism. Asian J Androl 2014; 16 (2) 232-238
79 Setji TL, Brown AJ. Polycystic ovary syndrome: update on diagnosis and treatment. Am J Med 2014; (e-pub ahead of print) doi: 0.1016/j.amjmed.2014.04.017
80 Devin JK, Johnson JE, Eren M , et al. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 2007; 39 (1) 9-16
81 Kyei-Mensah AA, LinTan S, Zaidi J, Jacobs HS. Relationship of ovarian stromal volume to serum androgen concentrations in patients with polycystic ovary syndrome. Hum Reprod 1998; 13 (6) 1437-1441
82 Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet 2010; 281 (1) 35-42
83 Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003; 24 (2) 183-217
84 Escobar-Morreale HF, Carmina E, Dewailly D , et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2012; 18 (2) 146-170
85 Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23 (3) 462-477
86 Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012; 5: CD003053
87 Legro RS, Barnhart HX, Schlaff WD , et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356 (6) 551-566
88 Moghetti P. For what reasons should metformin be used in the management of polycystic ovary syndrome?. J Endocrinol Invest 2012; 35 (1) 87-89
89 Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10 (3) 143-156
90 Wild RA, Carmina E, Diamanti-Kandarakis E , et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95 (5) 2038-2049
91 Tanis BC, van den Bosch MA, Kemmeren JM , et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345 (25) 1787-1793
92 Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008; 358 (12) 1262-1270
93 Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8 (11) 998-1005
94 Petitti DB. Hormonal contraceptives and arterial thrombosis—not risk-free but safe enough. N Engl J Med 2012; 366 (24) 2316-2318
95 Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003; 349 (15) 1443-1450
96 van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339: b2921
97 Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423
98 Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011; 342: d2151
99 Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342: d2139
100 Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003; 18 (3) 522-526
101 Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008. Am J Obstet Gynecol 2012; 207: 377.e1-8
102 Andersen P, Seljeflot I, Abdelnoor M , et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44 (5) 611-616
103 Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997; 46 (4) 454-457
104 Serdyńska-Szuster M, Banaszewska B, Spaczyński R, Pawelczyk L. Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome [in Polish]. Ginekol Pol 2011; 82 (4) 259-264
105 de Jager J, Kooy A, Schalkwijk C , et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Intern Med 2014; 275 (1) 59-70
106 Stener-Victorin E, Baghaei F, Holm G , et al. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial. Fertil Steril 2012; 97 (2) 501-508

Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome[*]

Authors

Hemostatic and Fibrinolytic Abnormalities in Polycystic Ovary Syndrome^[*]